Ipsen Pharma SAS
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$11.2M
Doctors Paid
96
Transactions
5,832
2024 Total
$4.6M
Payment Breakdown by Category
Research$9.8M (87.2%)
Consulting$233,802 (2.1%)
Travel$122,209 (1.1%)
Food & Beverage$14,344 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.8M | 5,592 | 87.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 22 | 9.2% |
| Consulting Fee | $233,802 | 52 | 2.1% |
| Travel and Lodging | $122,209 | 79 | 1.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $30,070 | 7 | 0.3% |
| Food and Beverage | $14,344 | 79 | 0.1% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $4,425 | 1 | 0.0% |
Payments by Type
Research
$9.8M
5,592 transactions
General
$1.4M
240 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | $5.5M | 0 | 3,751 |
| A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | $1.2M | 0 | 572 |
| A Prospective Observational International Study of Cabozantinib Tablets in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma in Adults | $594,121 | 0 | 382 |
| Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged greater than or equal to 14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy. | $443,989 | 1 | 98 |
| A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity | $389,988 | 0 | 137 |
| International, Multicentre, Observational, Prospective, Longitudinal Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort (AboLiSh) | $331,562 | 0 | 89 |
| An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1 | $330,584 | 0 | 17 |
| An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | $200,400 | 0 | 69 |
| Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD). | $157,199 | 0 | 31 |
| An International, Multicentre, Prospective, Single-Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction With a Guided Self-Rehabilitation Contract in Adult Subjects With Spastic Hemiparesis | $136,076 | 0 | 83 |
| An International, Multicentre, Prospective, Single-Arm Study to Assess the Effect on Voluntary Movements ofAbobotulinumtoxinA1500 U Administered in Both Upper and Lower Limbs in Conjunction With a Guided Self-Rehabilitation Contract in Adult Subjects With Spastic Hemiparesis | $131,770 | 0 | 312 |
| International, Multicentre, Observational, Prospective, Longitudinal Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort AboLiSh | $83,092 | 0 | 21 |
| An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors NETs | $80,912 | 0 | 2 |
| A Multicentre, Open-Label Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2) | $67,985 | 0 | 1 |
| An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs) | $44,476 | 0 | 2 |
| A Multicentre, Randomised, Dose-confirmation, Factorial Phase II Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour GEP-NET | $32,300 | 0 | 2 |
| An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A BoNT-A Injections In Subjects Suffering From Idiopathic Cervical Dystonia CD - Pharmaco-Economic Impact | $19,422 | 1 | 9 |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) | $12,700 | 0 | 4 |
| A Multicentre, Open-Label Phase III Study to Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga OPS202 PETCT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 SSTR2 | $9,725 | 0 | 2 |
| An International Multicentre, Open-Label First in Human Phase III Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1 | $8,750 | 0 | 1 |
| A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot Lanreotide Injection in the Treatment of Carcinoid Syndrome | $2,025 | 0 | 2 |
| Dysport Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 (CONTENT1) | $1,950 | 0 | 2 |
| International Multicentre Validation Study of SAGIT Instrument in Acromegaly | $1,344 | 1 | 1 |
| An International Multicentre Open-Label First in Human Phase I/II Study to Evaluate the Safety Tolerability Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1 | $1,005 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Jeffrey Edelson, M.d, M.D | Pulmonary Disease | Philadelphia, PA | $77,700 | $0 |
| Atul Patel, M.d, M.D | Physical Medicine & Rehabilitation | Overland Park, KS | $40,642 | $0 |
| Philip Charles, Md, MD | Neurological Surgery | Nashville, TN | $30,036 | $0 |
| Alberto Esquenazi, Md, MD | Physical Medicine & Rehabilitation | Philadelphia, PA | $22,118 | $0 |
| Chaitanya Divgi, Md, MD | Nuclear Medicine | New York, NY | $20,335 | $0 |
| Nizar Tannir, M.d, M.D | Medical Oncology | Houston, TX | $14,537 | $0 |
| Dr. Sumanta Pal, Md, MD | Internal Medicine | Duarte, CA | $13,873 | $0 |
| Dr. Richard Trosch, M.d, M.D | Neurology | Farmington Hills, MI | $13,293 | $0 |
| Richard Zorowitz, M.d, M.D | Physical Medicine & Rehabilitation | Washington, DC | $12,900 | $0 |
| Dr. Lee Chung, M.d, M.D | Vascular Neurology | Salt Lake City, UT | $11,908 | $0 |
| Eric Jonasch, M.d, M.D | Medical Oncology | Houston, TX | $11,515 | $0 |
| Dr. Wuwei Feng, Md Ms, MD MS | Neurology | Charleston, SC | $11,321 | $0 |
| Giannoula Klement, Md, MD | Pediatric Hematology-Oncology | Boston, MA | $10,000 | $0 |
| Kris Kowdley, Md, MD | Gastroenterology | Seattle, WA | $9,545 | $0 |
| Michael Cecchini, Md, MD | Hematology | New Haven, CT | $7,906 | $0 |
| Dr. Gerald Lipshutz, Md, MD | Urology | Los Angeles, CA | $6,860 | $0 |
| Stuart Gordon, M.d, M.D | Gastroenterology | Detroit, MI | $6,638 | $0 |
| Dr. Mitchell Shiffman, Md, MD | Gastroenterology | Newport News, VA | $6,225 | $0 |
| Dr. Andrew Hendifar, Md, Mph, MD, MPH | Internal Medicine | West Hollywood, CA | $6,090 | $0 |
| Dr. David Simpson, M.d, M.D | Neurology | New York, NY | $5,579 | $0 |
| Dr. Cynthia Comella, Md, MD | Neurology | Chicago, IL | $5,505 | $0 |
| Steven Edgley, Md, MD | Physical Medicine & Rehabilitation | Salt Lake City, UT | $4,502 | $0 |
| Yair Lotan, Md, MD | Urology | Dallas, TX | $4,425 | $0 |
| Wolfgang Weber, Md, MD | Nuclear Imaging & Therapy | New York, NY | $4,409 | $0 |
| Dr. Stephen Silberstein, M.d, M.D | Neurology | Philadelphia, PA | $4,260 | $0 |
About Ipsen Pharma SAS
Ipsen Pharma SAS has made $11.2M in payments to 96 healthcare providers, recorded across 5,832 transactions in the CMS Open Payments database. In 2024, the company paid $4.6M. The top product by payment volume is Dysport ($6.2M).
Payments were distributed across 31 medical specialties. The top specialty by payment amount is Physical Medicine & Rehabilitation ($101,923 to 22 doctors).
Payment categories include: Food & Beverage ($14,344), Consulting ($233,802), Research ($9.8M), Travel & Lodging ($122,209).
Ipsen Pharma SAS is associated with 1 products in the CMS Open Payments database.